[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-384775-105":59,"doc-detail-384775-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-nomogram-for-the-prediction-of-the-survival-of-patients-with-advanced-non-small-cell-lung-cancer-and-interstitial-lung-disease","A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease","","Lung cancer frequently coexists with interstitial lung disease (ILD), and combined comorbidity leads to poor overall survival (OS). This study develops and internally validates a prognostic nomogram to predict OS in patients with advanced non-small cell lung cancer (NSCLC) with and without ILD. Patients with wild-type gene advanced NSCLC receiving first-line chemotherapy (2014–2019) were analyzed using Kaplan–Meier curves and Cox regression, with calibration for validation, showing ILD-associated survival differences and significant independent predictors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-nomogram-for-the-prediction-of-the-survival-of-patients-with-advanced-non-small-cell-lung-cancer-and-interstitial-lung-disease/384775/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-nomogram-for-the-prediction-of-the-survival-of-patients-with-advanced-non-small-cell-lung-cancer-and-interstitial-lung-disease/384775.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of developing the nomogram in this study?","Question",{"text":112,"@type":113},"To predict overall survival (OS) for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the patients included in the analysis?",{"text":117,"@type":113},"Patients with wild-type gene advanced NSCLC who underwent first-line chemotherapy between 2014 and 2019, including those with and without ILD, were enrolled under defined inclusion and exclusion criteria.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were independently associated with prognosis in multivariate analysis?",{"text":121,"@type":113},"Lymphocyte count, partial pressure of oxygen (PaO2), and chemotherapy regimen were independently associated with prognosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},384775,1790367477,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","DOI: 10. 1002/cam4 .5852  \nRESEAR CH ARTICLE  \nA nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease  \nWeigang Xiu1 | Jincheng Zheng2 | Yuwen Zhou1 | He Du3 | Jiayu Li3 | Wei Li3 | Fei Zhou3  | Caicun Zhou3  | Fengying Wu3   \n1Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, PR China  \n2Jinhua Municipal Central Hospital, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Zhejiang, 321099, PR China 3Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, PR China  \nCorrespondence  \nFengying Wu, Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China  \nEmail: [fywu@163.com](fywu@163.com)  \nFunding information  \nClinical Research Plan of SHDC, Grant/ Award Number: SHDC2020CR4001; National Natural Science Foundation of China, Grant/Award Number:  \n81902314; Shanghai Nature Science Foundation, Grant/Award Number:  \n20ZR1447100  \nAbstract  \nBackground: Lung cancer is frequently accompanied by interstitial lung disease (ILD), and the overall survival (OS) of patients with these comorbidities is poor. Thus, we developed a nomogram for the prediction of the OS of patients with advanced non-small cell lung cancer (NSCLC) and ILD.  \nPatients and Methods: Patients with wild-type gene advanced NSCLC with and without ILD who underwent chemotherapy between 2014 and 2019 were enrolled in the present study. The 0.5-and 1-year progression-free survival (PFS) and overall survival (OS) times of patients with and without ILD were determined using the Kaplan–Meier method. Cox regression was used to assess the prognostic value of clinical factors for patients with ILD. Based on the multivariate regression results, a nomogram for survival prediction was developed. The nomogram was validated using calibration curve.  \nResults: Data from 155 patients with lung cancer and ILD and 118 matched patients with lung cancer alone who were receiving first-line chemotherapy were analyzed. The first-line chemotherapy regimens were paclitaxel +carboplatin, pemetrexed +carboplatin, gemcitabine +carboplatin, and other. The median PFS and OS were significantly shorter in patients with than in those without ILD (3.0 vs. 7.0 months [p \u003C0.001] and 7.0 vs. 15.0 months (p \u003C0.001), respectively) . Multivariate analysis showed that the lymphocyte count (hazard ratio [HR] 2.38; 95% confidence interval [CI], 1.44–3.94; p = 0.01), partial pressure of oxygen (PaO2; HR, 1.37; 95% CI, 1.03–1.82; p = 0.03), and chemotherapy regimen were independently associated with prognosis. The nomogram showed good discriminatory ability [C-index = 0.69 (95% CI, 0.49–0.82)] . Calibration curves showed that predicted and actual prognoses were consistent.  \nConclusion: This nomogram can aid the prediction of the OS of patients with advanced NSCLC and ILD.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  \nKEYWORDS  \nadvanced non-small cell lung cancer, chemotherapy, interstitial lung disease, nomogram, predictive factor  \n1 | INTRODUCTION  \nLung cancer is among the most common malignancies, causing about 25% of all cancer-related deaths worldwide.1 Nearly 85% of lung cancers diagnosed are non-small-cell lung cancer (NSCLC),2 for which interstitial lung disease (ILD) is an independent risk factor.3 The rate of NSCLC/ ILD comorbidity is high (5 .8%–15 .2%) .4  \nNSCLC and ILD have common underlying pathogenic mechanisms.5 Epithelial dysfunction, abnormal growth factor secretion, and the weakening of cellular interaction have been reported to be key factors in the cancer","cbCaiq6sSaP2V56s","https://ap.wps.com/l/cbCaiq6sSaP2V56s","pdf",1943705,"English","# Introduction\n# Materials and Methods\n## Patients and data collection","[{\"question\":\"What was the purpose of developing the nomogram in this study?\",\"answer\":\"To predict overall survival (OS) for patients with advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD).\"},{\"question\":\"Who were the patients included in the analysis?\",\"answer\":\"Patients with wild-type gene advanced NSCLC who underwent first-line chemotherapy between 2014 and 2019, including those with and without ILD, were enrolled under defined inclusion and exclusion criteria.\"},{\"question\":\"Which factors were independently associated with prognosis in multivariate analysis?\",\"answer\":\"Lymphocyte count, partial pressure of oxygen (PaO2), and chemotherapy regimen were independently associated with prognosis.\"}]","A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease | PDF",1790264959,25]